BACKGROUND Non-invasive evaluation for liver fibrosis is clinically important,especially in patients with undetectable hepatitis B virus(HBV)DNA treated with nucleoside analogs.AIM To clarify the monitoring power of h...BACKGROUND Non-invasive evaluation for liver fibrosis is clinically important,especially in patients with undetectable hepatitis B virus(HBV)DNA treated with nucleoside analogs.AIM To clarify the monitoring power of hepatitis B core-related antigen(HBcrAg)for hepatic histologic changes in patients with chronic hepatitis B(CHB)treated with entecavir.METHODS This prospective multicenter study used multiple ordinal and multivariate logistics regression analysis to assess variables associated with Ishak fibrosis score and regression for fibrosis regression,respectively,in 403 CHB patients,including 374 with entecavir for 72 weeks(291 underwent paired liver biopsy)and 29 as controls.RESULTS Level of HBcrAg correlated negatively with liver fibrosis staging(γ=-0.357,P<0.001)in hepatitis B e antigen(HBeAg)-positive patients,and positively with liver fibrosis staging in HBeAg-negative patients.Higher HBcrAg concentration was associated with younger age,HBeAg positive status,high HBV DNA loads,high level of hepatitis B surface antigen(HBsAg)and higher necroinflammation,but not with HBV genotype.Serum concentration of HBcrAg,basal core promoter/precore(BCP/PC)mutant,quantitation of HBsAg(qHBsAg)and platelet counts were independently associated with Ishak fibrosis score on multiple ordinal regression.HBV DNA was undetectable in 88.37%of patients treated with entecavir at week 72,while their level of HBcrAg was still detectable.A greater reduction in post-treatment HBcrAg concentration was associated with the regression of hepatic fibrosis and histological improvement.HBcrAg concentration>6.33 log IU/mL at baseline and logarithmic reduction>1.03 log IU/mL at week 72 were associated with a higher chance of regression of liver fibrosis and histological improvement,respectively.CONCLUSION HBcrAg level is associated with liver fibrosis progression.HBcrAg is an excellent monitor of hepatic histological changes,especially in CHB patients treated with nucleoside analogs.展开更多
加速康复外科(enhanced recovery after surgery,ERAS)理念的实施有益于外科患者术后加速康复,LEER模式[少痛(less pain)、早动(early move)、早食(early eat)、安心(reassuring)]下的ERAS体系则是为临床更好实施ERAS理念建立的系统、...加速康复外科(enhanced recovery after surgery,ERAS)理念的实施有益于外科患者术后加速康复,LEER模式[少痛(less pain)、早动(early move)、早食(early eat)、安心(reassuring)]下的ERAS体系则是为临床更好实施ERAS理念建立的系统、规范和标准化的工作方法与工作流程。经临床外科和外科联合具有综合属性的全科医学科建立的加速康复All in One病房的初期探索及应用取得了一系列有益结果,均证明LEER模式ERAS不仅能系统、全面、规范地执行ERAS措施,也可以将LEER-ERAS理念拓展应用到加速康复All in One病房共同协助外科患者围手术期的治疗及管理促进患者加速康复。在前期工作取得的成效基础上,将有益于患者治疗后加速康复的ERAS理念延伸、拓展成加速康复医学(enhanced recovery after treatment,ERAT)理念来拓宽加速康复All in One病房的应用范围,包括应用到临床所有的非外科专业科室,其目的是探索和研究如何应用ERAT理念构建医院ERAT临床应用体系来促进患者康复。展开更多
基金Supported by Chinese Ministry of Science and Technology Grants the Major Science and Technology Special Project Fund Scheme,No.2013ZX10005002Beijing the Special Clinical Application Research and Translational Grants,No.Z151100004015221
文摘BACKGROUND Non-invasive evaluation for liver fibrosis is clinically important,especially in patients with undetectable hepatitis B virus(HBV)DNA treated with nucleoside analogs.AIM To clarify the monitoring power of hepatitis B core-related antigen(HBcrAg)for hepatic histologic changes in patients with chronic hepatitis B(CHB)treated with entecavir.METHODS This prospective multicenter study used multiple ordinal and multivariate logistics regression analysis to assess variables associated with Ishak fibrosis score and regression for fibrosis regression,respectively,in 403 CHB patients,including 374 with entecavir for 72 weeks(291 underwent paired liver biopsy)and 29 as controls.RESULTS Level of HBcrAg correlated negatively with liver fibrosis staging(γ=-0.357,P<0.001)in hepatitis B e antigen(HBeAg)-positive patients,and positively with liver fibrosis staging in HBeAg-negative patients.Higher HBcrAg concentration was associated with younger age,HBeAg positive status,high HBV DNA loads,high level of hepatitis B surface antigen(HBsAg)and higher necroinflammation,but not with HBV genotype.Serum concentration of HBcrAg,basal core promoter/precore(BCP/PC)mutant,quantitation of HBsAg(qHBsAg)and platelet counts were independently associated with Ishak fibrosis score on multiple ordinal regression.HBV DNA was undetectable in 88.37%of patients treated with entecavir at week 72,while their level of HBcrAg was still detectable.A greater reduction in post-treatment HBcrAg concentration was associated with the regression of hepatic fibrosis and histological improvement.HBcrAg concentration>6.33 log IU/mL at baseline and logarithmic reduction>1.03 log IU/mL at week 72 were associated with a higher chance of regression of liver fibrosis and histological improvement,respectively.CONCLUSION HBcrAg level is associated with liver fibrosis progression.HBcrAg is an excellent monitor of hepatic histological changes,especially in CHB patients treated with nucleoside analogs.
文摘加速康复外科(enhanced recovery after surgery,ERAS)理念的实施有益于外科患者术后加速康复,LEER模式[少痛(less pain)、早动(early move)、早食(early eat)、安心(reassuring)]下的ERAS体系则是为临床更好实施ERAS理念建立的系统、规范和标准化的工作方法与工作流程。经临床外科和外科联合具有综合属性的全科医学科建立的加速康复All in One病房的初期探索及应用取得了一系列有益结果,均证明LEER模式ERAS不仅能系统、全面、规范地执行ERAS措施,也可以将LEER-ERAS理念拓展应用到加速康复All in One病房共同协助外科患者围手术期的治疗及管理促进患者加速康复。在前期工作取得的成效基础上,将有益于患者治疗后加速康复的ERAS理念延伸、拓展成加速康复医学(enhanced recovery after treatment,ERAT)理念来拓宽加速康复All in One病房的应用范围,包括应用到临床所有的非外科专业科室,其目的是探索和研究如何应用ERAT理念构建医院ERAT临床应用体系来促进患者康复。
